A Phase I, Open-Label, Dose Escalation Study of Weekly Dosing With BB-10901, Followed by a Phase II Efficacy Expansion
Phase of Trial: Phase I/II
Latest Information Update: 17 Jul 2012
At a glance
- Drugs Lorvotuzumab mertansine (Primary)
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 11 Oct 2010 Encouraging results were presented at ESMO 2010, as reported in an ImmunoGen Inc., media release.
- 01 Aug 2009 Results are being presented at the 13th World Conference on Lung Cancer, according to an Immunogen media release.
- 08 Jan 2009 Actual patient number reported as 32 by ClinicalTrials.gov.